Dawn brings more than 30 years of experience in drug and device development, spanning leadership roles across clinical research organizations, sites, and sponsors. Most recently, Dawn served as the Chief Growth Officer of WCG, a provider of clinical trial support services to sponsors, CROs, and sites. Prior to her role as Chief Growth Officer, Dawn served as COO and Executive Vice President, Research Strategy at Elligo Health Research. Her previous leadership positions include Chief Development Officer at Clinipace Clinical Research (now Caidya), where she expanded the company’s reach as a trusted partner to sponsors across multiple therapeutic areas. She has also served as President of Development Innovations at Sarah Cannon and as Senior Vice President and General Manager for Hematology/Oncology at inVentiv Health (now Syneos).
Recognized for her deep expertise in hematology and oncology, Dawn is known as a trusted industry leader with extensive client relationships and a proven track record of helping sponsors and research sites drive meaningful results. She is passionate about delivering outcomes that bring the industry closer to providing everyone with greater access to participate in clinical research.
